Rigel Pharmaceuticals, Inc. (RIGL) AI Stock Analysis

Rigel Pharmaceuticals, Inc. is a South San Francisco-based biotechnology company founded in 1996 that discovers and develops small molecule drugs for hematologic disorders, cancer, and rare immune diseases. Its commercialized offerings include Tavalisse, an oral spleen tyrosine kinase inhibitor for adult chronic immune thrombocytopenia, and Rezlidhia, a non-intensive monotherapy for adult relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In clinical development, the company has evaluated Fostamatinib in Phase III trials for warm autoimmune hemolytic anemia and COVID-19. Rigel also maintains clinical partnerships with Eli Lilly and Company, BerGenBio ASA, and Daiichi Sankyo.

Rigel delivered a 5-year revenue CAGR of 22.1% from FY2020 to FY2025. Following annual revenue declines of 19.4% in FY2022 to $120.2M and 2.8% in FY2023 to $116.9M, top-line growth rebounded 53.4% in FY2024 to $179.3M. In FY2025, revenue rose 64.1% to $294.3M, supported by a 93.3% gross margin and an operating margin of 42.6%. Net income reached $367.0M in FY2025, compared to $17.5M in FY2024 and net losses of -$25.1M in FY2023 and -$58.6M in FY2022. For the latest quarter ended June 30, 2026, revenue fell 22.6% year-over-year, and earnings decreased 73.2%.

As of June 30, 2026, Rigel held $95.3M in cash and short-term investments against total debt of $40.0M, resulting in net cash of $55.4M. The company maintains a current ratio of 1.95, total assets of $521.1M, and shareholders' equity of $425.4M, with a debt-to-equity ratio of 0.09. Cash generation improved significantly in recent periods, producing $75.7M in operating cash flow and $75.7M in free cash flow during FY2025. Over 5 years, the company's share count increased 14.4%.

Rigel trades at a trailing price-to-earnings multiple of 2.7x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward price-to-earnings ratio is 9.3x versus the peer median of 17.3x, while enterprise value to EBITDA sits at 9.1x against the peer median of 12.0x. The company has a market cap of $858.7M and an enterprise value of $856.6M. Over the past year, Rigel's stock gained 63.5%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of 36.0% lagged the S&P 500 return of 83.0%.

Consensus ratings include 3 Strong Buy and 2 Hold recommendations from Wall Street analysts. The mean price target is $63.00, representing a 37.0% premium over the last close of $45.97. For the fiscal year ending December 31, 2026, analysts project revenue of $305.7M and EPS of $3.54, which indicates a 44.9% decline in earnings per share. For the following fiscal year, 4 analysts estimate revenue to grow 21.9% to $372.8M and EPS to increase 39.4% to $4.94. Rigel beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Rigel Pharmaceuticals, Inc. (RIGL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RIGL income statement, RIGL balance sheet, RIGL key metrics, RIGL analyst forecast, RIGL chart. See the RIGL stock overview for the latest quote and news.